Sugi Predict

Sugi Predict / Compounds / SCHEMBL902952

SCHEMBL902952

SCHEMBL902952

Cc1cc(C(C)Nc2ccccc2)c2nc(N3CCOCC3)cc(=O)n2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CB P42338 20/20 1.00
▸ PIK3CA P42336 14/20 1.00
▸ PIK3CD O00329 8/20 1.00
▸ PIK3CG P48736 4/20 1.00
▸ PIK3R1 P27986 1/20 1.00
▸ CSNK1A1 P48729 1/20 1.00
▸ PTK2 Q05397 1/20 1.00
▸ CLK4 Q9HAZ1 1/20 1.00
▸ SRC P12931 1/20 0.77
▸ DDX6 P26196 1/20 0.77
▸ PDE4A P27815 1/20 0.77
▸ CSK P41240 1/20 0.77
▸ MTOR P42345 1/20 0.77
▸ PLK1 P53350 1/20 0.77
▸ PRKDC P78527 1/20 0.77
▸ PDE4B Q07343 1/20 0.77
▸ PDE4C Q08493 1/20 0.77
▸ PDE4D Q08499 1/20 0.77
▸ AURKB Q96GD4 1/20 0.77
▸ PI4KB Q9UBF8 1/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29358326 1.00 PIK3CB (1.00) PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1
SCHEMBL910109 0.92 PIK3CB (1.00) PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1
SCHEMBL909856 0.90 PIK3CB (0.83) PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1
SCHEMBL23482795 0.90 PIK3CB (0.83) PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1
SCHEMBL909993 0.90 PIK3CB (1.00) PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1
SCHEMBL12700775 0.90 PIK3CB (0.82) PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1
SCHEMBL910014 0.90 PIK3CB (1.00) PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1
SCHEMBL910346 0.90 PIK3CB (0.85) PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1
SCHEMBL910071 0.90 PIK3CB (0.81) PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1
SCHEMBL20694107 0.89 PIK3CB (0.79) PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1757 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122057023-A Use of Pik3cb inhibitors for the treatment of sjogren's disease 首都医科大学附属北京口腔医院 2026-05-19 — — CN claimed
US-20260078120-A1 SUBSTITUTED PYRIDOPYRIMIDINONES Mirati Therapeutics, Inc. (US) 2026-03-19 — — US claimed
US-20260053761-A1 USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER UNIV OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) 2026-02-26 — — US claimed
WO-2025264581-A1 P110 INHIBITORS FOR THE TREATMENT OF CANCER LEAPFROG BIO, INC. (US) 2025-12-26 — — WO claimed
WO-2025235403-A1 DIFFERENTIATION OF PANCREATIC ISLET CELLS VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-11-13 — — WO claimed
EP-4615506-A1 USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES Sahin, Fikret (TR) 2025-09-17 — — EP claimed
EP-4577544-A1 SUBSTITUTED PYRIDOPYRIMIDINONES Mirati Therapeutics, Inc. (US) 2025-07-02 — — EP claimed
EP-4561704-A2 USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER The University Of Vermont (US) 2025-06-04 — — EP claimed
EP-3828265-B1 IMPROVED T CELL COMPOSITIONS 2SEVENTY BIO INC (US) 2025-05-07 — — EP claimed
US-20250109444-A1 DNA HYPOMETHYLATION AS A PREDICTIVE MARKER FOR CANCER THERAPY FRED HUTCHINSON CANCER CENTER (US) 2025-04-03 — — US claimed
WO-2015002729-A2 CELL STABILIZATION BIOMATRICA, INC. (US) 2015-01-08 — — WO claimed
WO-2013029116-A1 METHOD FOR PREDICTING TREATMENT RESPONSIVENESS MONASH UNIVERSITY (AU) 2013-03-07 — — WO claimed
US-20120231015-A1 FRAGILE X MENTAL RETARDATION PROTEIN (FMRP), COMPOSITIONS, AND METHODS RELATED THERETO EMORY UNIVERSITY (US) 2012-09-13 — — US claimed
WO-2011056930-A2 FRAGILE X MENTAL RETARDATION PROTEIN (FMRP), COMPOSITIONS, AND METHODS RELATED THERETO EMORY UNIVERSITY (US) 2011-05-12 — — WO claimed
JP-4646626-B2 — — 2011-03-09 — — JP claimed
US-7598377-B2 (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy ASTRAZENECA AB (SE) 2009-10-06 — — US claimed
US-20060276470-A1 (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy ASTRAZENECA AB (SE) 2006-12-07 — — US claimed
JP-2006500361-A — — 2006-01-05 — — JP claimed
EP-1537102-A1 INHIBITION OF PHSPHOINOSTIDE 3-DINASE BETA Kinacia Pty Ltd. (AU) 2005-06-08 — — EP claimed
WO-2004016607-A1 INHIBITION OF PHOSPHOINOSITIDE 3-KINASE BETA KINACIA PTY LTD. (AU) 2004-02-26 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250109444-A1 DNA HYPOMETHYLATION AS A PREDICTIVE MARKER FOR CANCER THERAPY DNMT1, DNMT3B, DNMT3A PIK3CB 331/4885PIK3CA 187/4885PIK3CD 306/4885
US-20260053761-A1 USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER THRA, THRB, TRHR PIK3CB 3531/4885PIK3CA 2438/4885PIK3CD 2996/4885
US-20060276470-A1 (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy PI4KA, PI4KB, PI4K2B PIK3CB 8/4885PIK3CA 16/4885PIK3CD 15/4885
US-20260078120-A1 SUBSTITUTED PYRIDOPYRIMIDINONES CBR1, CBR3, CNR1 PIK3CB 2831/4885PIK3CA 2749/4885PIK3CD 2892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.